ANIK at a glance
Anika Therapeutics, Inc. (ANIK, SEC CIK 898437) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 6, 2026 and Form 4 insider filings as recently as August 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Anika Therapeutics, Inc. (ANIK) reported revenue of $112.8 million (down 5.9% from FY2024) and a net loss of $10.9 million. Diluted EPS was -$0.76.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Anika Therapeutics, Inc. (ANIK) shares worth $106.6 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Fischetti Gary P on August 4, 2026 of 1,000 shares at $20.32 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $112.8M
- −5.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 24 funds
- $106.6M · +0 vs prior quarter
- Latest 8-K
- Nov 6, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to 2025 Form 10-K risk factors
- Carried-forward business risk: disclosed risks could materially affect future results
- Carried-forward uncertainty risk: unknown or currently immaterial risks could materially harm operations
Management Discussion & Analysis
- Revenue $30.6M, up 10% YoY from $27.8M, driven by Commercial Channel growth
- Gross margin 62% vs 56% YoY, with net loss $0.3M vs $3.2M
- Best segment Commercial Channel revenue $14.0M, up 17%; Integrity sales supported regenerative growth
- Cash $45.0M vs $57.5M at December 31, 2025; operating cash flow $2.8M vs $6.6M
- Hyalofast PMA not approvable; Cingal NDA submission targeted by December 31, 2027
AI summary of the ANIK 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue $30.6M, up 10%, with Commercial Channel growth 17% and OEM growth 5%
- Gross margin expanded to 62% from 56%, while adjusted EBITDA increased to $5.1M from $0.9M
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains financial results
Item EX-99.1: Item EX-99.1
- Q2 revenue $32.6M, up 16%, with Commercial Channel revenue up 17% to record $13.9M
- Gross margin expanded to 65%, driving $3.3M GAAP net income and $7.1M adjusted EBITDA
Item 1.01: Entry into a Material Definitive Agreement
- $50.0M senior revolving credit facility extended through July 10, 2031
- Potential $50.0M expansion, bringing maximum commitments to $100.0M subject to lender approval
AI summaries of ANIK 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ANIK
Don't miss the next ANIK filing
- Alerts as it files. A push when ANIK files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ANIK, by share count.
- Ask anything. An AI agent that reads every ANIK filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Fischetti Gary P | Buy | Aug 4, 2026 | 1,000 | $20.32 |
| Fischetti Gary P | Buy | Aug 3, 2026 | 1,000 | $20.75 |
| Fischetti Gary P | A | Jun 18, 2026 | 10,402 | - |
| CONLEY SHERYL L | A | Jun 18, 2026 | 10,402 | - |
| HENNEMAN JOHN B III | A | Jun 18, 2026 | 10,402 | - |
| Richard Stephen | A | Jun 18, 2026 | 10,402 | - |
| Capper Joseph H | A | Jun 18, 2026 | 10,402 | - |
| Griffin Stephen D. | F | Jun 3, 2026 | 3,769 | $14.41 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $119.9M | $112.8M |
| Gross Profit | - | $76.0M | $63.8M |
| Operating Income | - | -$5.1M | -$11.1M |
| Net Income | - | -$56.4M | -$10.9M |
| Gross Margin | - | 63.4% | 56.6% |
| Op. Margin | - | -4.3% | -9.8% |
| Net Margin | - | -47.0% | -9.6% |
| Balance Sheet | |||
| Total Assets | $270.6M | $202.7M | $190.3M |
| Equity | $212.3M | $154.0M | $143.5M |
| ROE | - | -36.6% | -7.6% |
| Per Share | |||
| EPS | - | $-3.83 | $-0.76 |
| Cash Flow | |||
| Operating CF | - | $5.4M | $11.2M |
| CapEx | - | $7.7M | $6.8M |
Source: XBRL data in Anika Therapeutics, Inc. (ANIK)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ANIK share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $106.6M |
| Q2 2026 | 24 | $82.6M |
| Q1 2026 | 23 | $84.3M |
| Q4 2025 | 22 | $55.5M |
| Q3 2025 | 22 | $48.8M |
| Q2 2025 | 23 | $48.5M |
| Q1 2025 | 21 | $46.6M |
| Q4 2024 | 17 | $46.5M |
- Prudential Financial+72.9K (+645%)
- Bank of America Corp+12.8K (+52%)
- Morgan Stanley+12.0K (+2%)
- Dimensional Fund Advisors+10.8K (+2%)
- Invesco Ltd+5.5K (+18%)
- AQR Capital Management−158.9K (-28%)
- BlackRock−38.6K (-3%)
- Two Sigma Investments−38.1K (-15%)
- D.E. Shaw & Co−27.5K (-11%)
- Renaissance Technologies LLC−22.7K (-5%)
- Citadel Advisors LLC+21.8K
- FMR LLC (Fidelity)−53.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 176 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ANIK filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 6, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 6, 2026 | - | Analysis | - |
| 4 | Aug 5, 2026 | - | - | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 10-Q | Jul 29, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 14, 2026 | - | Analysis | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | May 4, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 10-Q | Apr 30, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 29, 2026 | - | Analysis | - |
| SC 13G | Apr 29, 2026 | - | - | |
| 4 | Mar 23, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 11, 2026 | - | - | - |
| 4 | Mar 11, 2026 | - | - | - |
| 4 | Mar 11, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
- SKIN · Beauty Health CoSurgical & Medical Instruments & Apparatus
ANIK SEC filings: frequently asked questions
Which institutions hold ANIK stock?
As of September 30, 2026, the largest Anika Therapeutics, Inc. (ANIK) holders among the 13F filers tracked by SignalX were BlackRock ($27.7 million), Morgan Stanley ($12.3 million), Vanguard Capital Management LLC ($11.1 million), Dimensional Fund Advisors ($9.1 million), Renaissance Technologies LLC ($9.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ANIK's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Anika Therapeutics, Inc. (ANIK) reported revenue of $112.8 million (down 5.9% from FY2024) and a net loss of $10.9 million. Diluted EPS was -$0.76. The figures come from the XBRL data in the 10-K.
What did ANIK report in its latest 8-K?
Anika Therapeutics, Inc. (ANIK) filed an 8-K on November 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.
What are the latest ANIK SEC filings?
Anika Therapeutics, Inc. (ANIK) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 6, 2026 and a Form 4 insider filing on August 5, 2026.
What is ANIK's SEC CIK number?
Anika Therapeutics, Inc. (ANIK)'s SEC Central Index Key (CIK) is 898437. EDGAR lists every ANIK filing under that number.
Ask anything about ANIK
The research agent reads ANIK's filings, financials, insider trades and 13F holders, then answers with sources.